SCHEMBL9997334

SCHEMBL9997334

Cc1ccc(F)cc1S(=O)(=O)Nc1ccc(C(=O)O)c(O)c1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.73
HSD17B10 Q99714 2/20 0.73
PFKFB3 Q16875 3/20 0.56
HPGD P15428 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
TSHR P16473 2/20 0.56
USP2 O75604 1/20 0.56
FABP4 P15090 2/20 0.52
FABP5 Q01469 2/20 0.52
IDH1 O75874 4/20 0.50
KDM4E B2RXH2 1/20 0.50
MCL1 Q07820 1/20 0.49
GAA P10253 1/20 0.48
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
MEP1B Q16820 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9997159 0.87 HSD17B10 (0.62) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL9996982 0.87 ALDH1A1 (0.81) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL9997031 0.85 ALDH1A1 (0.73) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL9997320 0.84 ALDH1A1 (1.00) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL9996886 0.83 ALDH1A1 (0.74) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL28647932 0.83 ALDH1A1 (0.70) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL19281319 0.82 HSD17B10 (0.66) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL12325921 0.80 POLB (0.66) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL9997508 0.80 ALDH1A1 (0.81) ALDH1A1HSD17B10PFKFB3HPGDMEN1
SCHEMBL9997030 0.79 PFKFB3 (0.70) ALDH1A1HSD17B10PFKFB3HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 ALDH1A1 1943/4885HSD17B10 1255/4885PFKFB3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.